Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 46Prostate Adenocarcinoma 3Neoplasms 3Adenocarcinoma 2Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Prostatic Diseases 1PSA Level Greater Than Two 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Granulosa cell tumor of the ovary 1Genital Neoplasms, Male 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma 1

Interventions

nirogacestat 1luspatercept 1luprolide acetate gel depot 1exemestane 1etoposide phosphate 1darolutamide 1X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Leuprolide 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Granulosa cell tumor of the ovary × luprolide acetate gel depot × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡